These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 19773549)
1. The fifth transmembrane domain of angiotensin II Type 1 receptor participates in the formation of the ligand-binding pocket and undergoes a counterclockwise rotation upon receptor activation. Domazet I; Martin SS; Holleran BJ; Morin ME; Lacasse P; Lavigne P; Escher E; Leduc R; Guillemette G J Biol Chem; 2009 Nov; 284(46):31953-61. PubMed ID: 19773549 [TBL] [Abstract][Full Text] [Related]
2. The second transmembrane domain of the human type 1 angiotensin II receptor participates in the formation of the ligand binding pocket and undergoes integral pivoting movement during the process of receptor activation. Domazet I; Holleran BJ; Martin SS; Lavigne P; Leduc R; Escher E; Guillemette G J Biol Chem; 2009 May; 284(18):11922-9. PubMed ID: 19276075 [TBL] [Abstract][Full Text] [Related]
3. Analysis of the third transmembrane domain of the human type 1 angiotensin II receptor by cysteine scanning mutagenesis. Martin SS; Boucard AA; Clément M; Escher E; Leduc R; Guillemette G J Biol Chem; 2004 Dec; 279(49):51415-23. PubMed ID: 15452107 [TBL] [Abstract][Full Text] [Related]
4. Analysis of transmembrane domains 1 and 4 of the human angiotensin II AT1 receptor by cysteine-scanning mutagenesis. Yan L; Holleran BJ; Lavigne P; Escher E; Guillemette G; Leduc R J Biol Chem; 2010 Jan; 285(4):2284-93. PubMed ID: 19940150 [TBL] [Abstract][Full Text] [Related]
5. Constitutive activation of the angiotensin II type 1 receptor alters the spatial proximity of transmembrane 7 to the ligand-binding pocket. Boucard AA; Roy M; Beaulieu ME; Lavigne P; Escher E; Guillemette G; Leduc R J Biol Chem; 2003 Sep; 278(38):36628-36. PubMed ID: 12842881 [TBL] [Abstract][Full Text] [Related]
6. Activation of the angiotensin II type 1 receptor leads to movement of the sixth transmembrane domain: analysis by the substituted cysteine accessibility method. Martin SS; Holleran BJ; Escher E; Guillemette G; Leduc R Mol Pharmacol; 2007 Jul; 72(1):182-90. PubMed ID: 17446269 [TBL] [Abstract][Full Text] [Related]
7. Analysis by substituted cysteine scanning mutagenesis of the fourth transmembrane domain of the CXCR4 receptor in its inactive and active state. Boulais PE; Escher E; Leduc R Biochem Pharmacol; 2013 Feb; 85(4):541-50. PubMed ID: 23219524 [TBL] [Abstract][Full Text] [Related]
8. Identification of transmembrane domain 3, 4 & 5 residues that contribute to the formation of the ligand-binding pocket of the urotensin-II receptor. Sainsily X; Cabana J; Boulais PE; Holleran BJ; Escher E; Lavigne P; Leduc R Biochem Pharmacol; 2013 Dec; 86(11):1584-93. PubMed ID: 24084430 [TBL] [Abstract][Full Text] [Related]
9. Identification of transmembrane domain 6 & 7 residues that contribute to the binding pocket of the urotensin II receptor. Holleran BJ; Domazet I; Beaulieu ME; Yan LP; Guillemette G; Lavigne P; Escher E; Leduc R Biochem Pharmacol; 2009 Apr; 77(8):1374-82. PubMed ID: 19426676 [TBL] [Abstract][Full Text] [Related]
10. Chloroethylclonidine and 2-aminoethyl methanethiosulfonate recognize two different conformations of the human alpha(2A)-adrenergic receptor. Marjamäki A; Frang H; Pihlavisto M; Hoffrén AM; Salminen T; Johnson MS; Kallio J; Javitch JA; Scheinin M J Biol Chem; 1999 Jul; 274(31):21867-72. PubMed ID: 10419505 [TBL] [Abstract][Full Text] [Related]
11. Activation induces structural changes in the liganded angiotensin II type 1 receptor. Clément M; Cabana J; Holleran BJ; Leduc R; Guillemette G; Lavigne P; Escher E J Biol Chem; 2009 Sep; 284(39):26603-12. PubMed ID: 19635801 [TBL] [Abstract][Full Text] [Related]
12. The conserved cysteine 7.38 residue is differentially accessible in the binding-site crevices of the mu, delta, and kappa opioid receptors. Xu W; Chen C; Huang P; Li J; de Riel JK; Javitch JA; Liu-Chen LY Biochemistry; 2000 Nov; 39(45):13904-15. PubMed ID: 11076532 [TBL] [Abstract][Full Text] [Related]
13. Long range effect of mutations on specific conformational changes in the extracellular loop 2 of angiotensin II type 1 receptor. Unal H; Jagannathan R; Bhatnagar A; Tirupula K; Desnoyer R; Karnik SS J Biol Chem; 2013 Jan; 288(1):540-51. PubMed ID: 23139413 [TBL] [Abstract][Full Text] [Related]
14. Comparison of the amino acid residues in the sixth transmembrane domains accessible in the binding-site crevices of mu, delta, and kappa opioid receptors. Xu W; Li J; Chen C; Huang P; Weinstein H; Javitch JA; Shi L; de Riel JK; Liu-Chen LY Biochemistry; 2001 Jul; 40(27):8018-29. PubMed ID: 11434771 [TBL] [Abstract][Full Text] [Related]
15. The constitutively active N111G-AT1 receptor for angiotensin II maintains a high affinity conformation despite being uncoupled from its cognate G protein Gq/11alpha. Auger-Messier M; Clement M; Lanctot PM; Leclerc PC; Leduc R; Escher E; Guillemette G Endocrinology; 2003 Dec; 144(12):5277-84. PubMed ID: 12960024 [TBL] [Abstract][Full Text] [Related]
16. Cysteine 2.59(89) in the second transmembrane domain of human CB2 receptor is accessible within the ligand binding crevice: evidence for possible CB2 deviation from a rhodopsin template. Zhang R; Hurst DP; Barnett-Norris J; Reggio PH; Song ZH Mol Pharmacol; 2005 Jul; 68(1):69-83. PubMed ID: 15840841 [TBL] [Abstract][Full Text] [Related]
17. Constitutive activation of the beta2 adrenergic receptor alters the orientation of its sixth membrane-spanning segment. Javitch JA; Fu D; Liapakis G; Chen J J Biol Chem; 1997 Jul; 272(30):18546-9. PubMed ID: 9228019 [TBL] [Abstract][Full Text] [Related]
18. The active and the inactive form of the hAT1 receptor have an identical ligand-binding environment: an MPA study on a constitutively active angiotensin II receptor mutant. Clément M; Chamberland C; Pérodin J; Leduc R; Guillemette G; Escher E J Recept Signal Transduct Res; 2006; 26(5-6):417-33. PubMed ID: 17118790 [TBL] [Abstract][Full Text] [Related]
19. Molecular mechanisms of constitutive activity: mutations at position 111 of the angiotensin AT1 receptor. Nikiforovich GV; Mihalik B; Catt KJ; Marshall GR J Pept Res; 2005 Nov; 66(5):236-48. PubMed ID: 16218991 [TBL] [Abstract][Full Text] [Related]
20. Selected cysteine residues in transmembrane domains of mu-opioid receptor are critical for effects of sulfhydryl reagents. Deng HB; Guang W; Wang JB J Pharmacol Exp Ther; 2000 Apr; 293(1):113-20. PubMed ID: 10734160 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]